Targeting Human Papillomavirus-Associated Cancer by Oncoprotein-Specific Recombinant Antibodies

In recent decades, recombinant antibodies against specific antigens have shown great promise for the therapy of infectious diseases and cancer. Human papillomaviruses (HPVs) are involved in the development of around 5% of all human cancers and HPV16 is the high-risk genotype with the highest prevale...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-09, Vol.22 (17), p.9143
Main Authors: Donà, Maria Gabriella, Di Bonito, Paola, Chiantore, Maria Vincenza, Amici, Carla, Accardi, Luisa
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Binding sites
Cancer
Clinical trials
Cloning
Gene expression
Genetic engineering
Genomes
Genotypes
Human papillomavirus
Immune system
Infectious diseases
Oncoproteins
Papillomaviridae
Proteins
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent decades, recombinant antibodies against specific antigens have shown great promise for the therapy of infectious diseases and cancer. Human papillomaviruses (HPVs) are involved in the development of around 5% of all human cancers and HPV16 is the high-risk genotype with the highest prevalence worldwide, playing a dominant role in all HPV-associated cancers. Here, we describe the main biological activities of the HPV16 E6, E7, and E5 oncoproteins, which are involved in the subversion of important regulatory pathways directly associated with all known hallmarks of cancer. We then review the state of art of the recombinant antibodies targeted to HPV oncoproteins developed so far in different formats, and outline their mechanisms of action. We describe the advantages of a possible antibody-based therapy against the HPV-associated lesions and discuss the critical issue of delivery to tumour cells, which must be addressed in order to achieve the desired translation of the antibodies from the laboratory to the clinic.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms22179143